Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Preclinical studies on FK-317 presented at cancer meeting

Oct. 28, 1997

DAB-720: a new EGF receptor TK inhibitor from Mitsubishi Chemical

Oct. 28, 1997

Mechanism of action and in vivo antitumor efficacy reported for CS-682

Oct. 28, 1997

Novel antiangiogenic agent with oral activity in animal model of breast cancer

Oct. 28, 1997

SuperGen files supplemental NDA for Nipent

Oct. 27, 1997

Apoptotic effects described for antiestrogen

Oct. 27, 1997

Possible MDR-modulating effect described for E-6123, a PAF antagonist

Oct. 27, 1997

Antiangiogenic agent TNP-470 suppresses tumorigenesis in animal model

Oct. 27, 1997

Mechanism of action elucidated for anthracycline developed by Sumitomo

Oct. 27, 1997

TOP-53: preclinical antitumor activity and pharmacokinetics

Oct. 27, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...